Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 16/20 | 0.71 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | CSK | P41240 | 2/20 | 0.61 |
| ▸ | IGF1R | P08069 | 1/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.61 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.61 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.61 |
| ▸ | CDK2 | P24941 | 1/20 | 0.61 |
| ▸ | JAK3 | P52333 | 1/20 | 0.61 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.49 |
| ▸ | FLT3 | P36888 | 3/20 | 0.49 |
| ▸ | FLT4 | P35916 | 2/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | LYN | P07948 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5046799 | 0.98 | AURKA (0.70) | AURKAAURKBEGFRKDRCSK | |
| SCHEMBL5045499 | 0.94 | AURKA (0.73) | AURKAAURKBEGFRKDRCSK | |
| SCHEMBL5044923 | 0.94 | AURKA (0.70) | AURKAAURKBEGFRKDRCSK | |
| SCHEMBL4367113 | 0.92 | AURKA (0.76) | AURKAAURKBEGFRKDRCSK | |
| SCHEMBL5045138 | 0.90 | AURKA (0.75) | AURKAAURKBEGFRKDRCSK | |
| SCHEMBL5048661 | 0.90 | AURKA (0.69) | AURKAAURKBEGFRKDRCSK | |
| SCHEMBL5041104 | 0.90 | AURKA (0.68) | AURKAAURKBEGFRKDRCSK | |
| SCHEMBL5049569 | 0.90 | AURKA (0.78) | AURKAAURKBEGFRKDRCSK | |
| SCHEMBL5049573 | 0.90 | AURKA (0.78) | AURKAAURKBEGFRKDRCSK | |
| SCHEMBL3892628 | 0.89 | AURKA (0.73) | AURKAAURKBEGFRKDRCSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407946-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2008-08-05 | — | — | US | disclosed |
| US-20060058523-A1 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1575946-A1 | QUINAZOLINE COMPOUNDS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| WO-2004058752-A1 | QUINAZOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058523-A1 | Quinazoline compounds | NDUFS5, ABL1, NDUFS7 | AURKA 509/4885AURKB 735/4885EGFR 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.